title: Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism.
abstract: To establish the prevalence of antibodies against beta2-glycoprotein I (beta2GPI) in unselected patients with venous thromboembolism, as well as the association with antiphospholipid antibodies (aPL) and a history of previous thromboembolism, we investigated the presence of these antibodies in 227 consecutive patients with acute deep vein thrombosis or pulmonary embolism, of whom 63 were carriers of aPL with or without lupus anticoagulant (LA), and seven were carriers of LA alone. The presence of antibodies against beta2GPI was demonstrated in 19 patients [8.4%; 95% confidence interval (CI), 4.5-11.3%]. All of them belonged to the group of 63 patients with aPL (30.2%). A history of a previous thromboembolism was identified in 11 of the 19 patients with anti-beta2GPI antibodies (57.9%) and in 45 of the 208 patients without these antibodies [21.6%; odds ratio (OR)=4.98; 95% CI, 1.89-13.1; p<0.0005]. In the subgroup of patients with aPL and/or LA, the rate of recurrent thromboembolism among patients with anti-beta2GPI antibodies (11 of 19, 57.9%) was significantly higher than that observed in patients without these antibodies (15 of 51, 29.4%; OR=3.3; 95% CI, 1.1-9.83; p=0.28). We conclude that in patients with acute venous thromboembolism the prevalence of antibodies against beta2GPI is unexpectedly high. The presence of these antibodies seems to identify a subgroup of patients with antiphospholipid antibodies who have a peculiarly high risk of thrombotic recurrences. Further prospective studies are indicated to better define the role of anti-beta2GPI antibodies in the development of recurrent thromboembolism.
authors.affiliation: Department of Medical and Surgical Sciences, University of Padua Medical School, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Zanon
authors.forename: P
authors.initials: P
authors.lastname: Prandoni
authors.forename: F
authors.initials: F
authors.lastname: Vianello
authors.forename: G
authors.initials: G
authors.lastname: Saggiorato
authors.forename: G
authors.initials: G
authors.lastname: Carraro
authors.forename: P
authors.initials: P
authors.lastname: Bagatella
authors.forename: A
authors.initials: A
authors.lastname: Girolami
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood*; D017152:Antibodies, Antiphospholipid / Q000097:blood; D001053:Apolipoproteins / Q000276:immunology; D005260:Female; D006023:Glycoproteins / Q000097:blood / Q000276:immunology*; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000276:immunology*; D020246:Venous Thrombosis / Q000097:blood / Q000276:immunology*; D053482:beta 2-Glycoprotein I
chemical_list: D000906:Antibodies; D017152:Antibodies, Antiphospholipid; D001053:Apolipoproteins; D006023:Glycoproteins; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I